GAPDHP14: A Drug Target / Disease Biomarker (G54050)

Target Name: GAPDHP14

NCBI ID: G54050

GAPDHP14

Other Name(s): glyceraldehyde-3-phosphate dehydrogenase pseudogene 14 | GAPDP14 | Glyceraldehyde-3-phosphate dehydrogenase pseudogene 14 | Glycerinaldehyde-3-phosphate dehydrogenase pseudogene

GAPDHP14: A Drug Target / Disease Biomarker

GAPDHP14 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation has been associated with the development of certain diseases, which has led to its potential as a therapeutic target.

GAPDHP14 is a gene that encodes a protein known as GAPDHP14, which is a part of the G-protein-coupled receptor (GPCR) family. GPCR is a large family of transmembrane proteins that play a crucial role in cellular signaling, including the regulation of ion channels, tyrosine signaling, and intracellular signaling pathways. GAPDHP14 is a member of the D1 subfamily of GPCR, which is characterized by the presence of a specific genetic variation called an insertion/deletion (I/D) event.

The I/D event that is present in GAPDHP14 has led to the formation of a truncated protein that is missing the last 150 amino acids. This loss of function has led to the decreased activity of GAPDHP14, which has been shown to play a role in various cellular processes, including cell signaling, cell division, and tissue remodeling.

GAPDHP14 has been associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that individuals with certain genetic variations, including those in GAPDHP14, are at increased risk for the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, GAPDHP14 has been implicated in the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

GAPDHP14 has also been shown to be involved in the regulation of cellular signaling pathways that are involved in cancer progression. For example, studies have shown that the activity of the oncogene transforming growth factor (TGF-β) is regulated by GAPDHP14, which has been shown to play a role in the regulation of TGF-β signaling. TGF-β is a potent regulator of cell signaling pathways that is involved in various cellular processes, including cell growth, differentiation, and inflammation.

In addition to its potential as a drug target or biomarker, GAPDHP14 has also been identified as a potential therapeutic approach for the treatment of various diseases. For example, studies have shown that inhibiting the activity of GAPDHP14 has the potential to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, GAPDHP14 has been shown to be involved in the regulation of cellular signaling pathways that are involved in cancer progression, which suggests that it may have the potential to be a useful target for cancer therapies.

Overall, GAPDHP14 is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Its unique genetic variation has been associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, GAPDHP14 has been shown to play a role in the regulation of cellular signaling pathways that are involved in cancer progression, which suggests that it may have the potential to be a useful target for cancer therapies. Further research is needed to fully understand the potential of GAPDHP14 as a drug target or biomarker.

Protein Name: Glyceraldehyde-3-phosphate Dehydrogenase Pseudogene 14

The "GAPDHP14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAPDHP14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets